TNXP — Tonix Pharmaceuticals Holding Share Price
0.000.00%
Last trade - 00:00- $121.18m
- $100.93m
- $7.77m
- 17
- 14
- 36
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.63 | ||
| Price to Tang. Book | 1.64 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -177.36% | ||
| Return on Equity | -138.69% | ||
| Operating Margin | -1253.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 7.77 | 12.64 | 17.25 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Directors
- Seth Lederman CHM (63)
- Bradley Saenger CFO (47)
- Jessica Morris COO (43)
- Gregory Sullivan SEC (55)
- James Treco LED (65)
- Carolyn Taylor DRC (62)
- Richard Bagger IND (61)
- Margaret Bell IND (61)
- Daniel Goodman IND (60)
- David Grange IND (73)
- Adeoye Olukotun IND (76)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 16th, 2007
- Public Since
- March 29th, 2010
- No. of Employees
- 103
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 6,434,881
- Address
- 26 Main Street, Suite 101, CHATHAM, 07928
- Web
- https://www.tonixpharma.com/
- Phone
- +1 2129809155
- Auditors
- EisnerAmper LLP
Upcoming Events for TNXP
Tonix Pharmaceuticals Holding Corp Annual Shareholders Meeting
Q2 2025 Tonix Pharmaceuticals Holding Corp Earnings Release
Similar to TNXP
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Aptose Biosciences
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Tonix Pharmaceuticals Holding share price?
As of Today at 22:43 UTC, shares in Tonix Pharmaceuticals Holding are trading at $23.03. This share price information is delayed by 15 minutes.
How has the Tonix Pharmaceuticals Holding share price performed this year?
Shares in Tonix Pharmaceuticals Holding last closed at $23.03 and the price had moved by -97.91% over the past 365 days. In terms of relative price strength the Tonix Pharmaceuticals Holding share price has underperformed the S&P500 Index by -98.07% over the past year.
What are the analyst and broker recommendations for Tonix Pharmaceuticals Holding?
The overall consensus recommendation for Tonix Pharmaceuticals Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tonix Pharmaceuticals Holding dividend yield?
Tonix Pharmaceuticals Holding does not currently pay a dividend.
Does Tonix Pharmaceuticals Holding pay a dividend?
Tonix Pharmaceuticals Holding does not currently pay a dividend.
When does Tonix Pharmaceuticals Holding next pay dividends?
Tonix Pharmaceuticals Holding does not currently pay a dividend.
How do I buy Tonix Pharmaceuticals Holding shares?
To buy shares in Tonix Pharmaceuticals Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tonix Pharmaceuticals Holding?
As of the previous close price of $23.03, shares in Tonix Pharmaceuticals Holding had a market capitalisation of $121.18m.
Where are Tonix Pharmaceuticals Holding shares listed?
Here are the trading details for Tonix Pharmaceuticals Holding:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TNXP
What kind of share is Tonix Pharmaceuticals Holding?
Based on an overall assessment of its quality, value and momentum Tonix Pharmaceuticals Holding is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tonix Pharmaceuticals Holding share price forecast for 2025?
The analyst consensus target price for shares in Tonix Pharmaceuticals Holding is $583.33. That is 2432.91% above the last closing price of $23.03.
Analysts covering Tonix Pharmaceuticals Holding currently have a consensus Earnings Per Share (EPS) forecast of -$1,844.68 for the next financial year.
Find out moreWhat is the trend in the Tonix Pharmaceuticals Holding share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tonix Pharmaceuticals Holding. Over the past six months, its share price has outperformed the S&P500 Index by +57.54%.
As of the last closing price of $23.03, shares in Tonix Pharmaceuticals Holding were trading -45.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tonix Pharmaceuticals Holding PE Ratio?
The Tonix Pharmaceuticals Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $23.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding's management team is headed by:
- Seth Lederman - CHM
- Bradley Saenger - CFO
- Jessica Morris - COO
- Gregory Sullivan - SEC
- James Treco - LED
- Carolyn Taylor - DRC
- Richard Bagger - IND
- Margaret Bell - IND
- Daniel Goodman - IND
- David Grange - IND
- Adeoye Olukotun - IND